. 2015 Nov 5;5:15832. doi: 10.1038/srep15832

Table 2. Summary of the gene expression validation in our second cohort and the TCGA TNBC cohort and discovery of TNBC specific genes.

graphic file with name srep15832-t2.jpg

We identified 185 significantly altered genes by comparing all TNBC samples (33) versus all matched normal samples (17) in our study cohort. We then compared all TNBC tumours (16) from our second cohort to all normal samples (4), which validated 99 of the 185 genes. Further, we used the TCGA TNBC cohort to compare 55 TNBC samples to 5 matched normal samples, which validated 95 of our initial 185 genes. By comparing the two sets of validated genes we found 66 common genes. To identify TNBC-specific genes, we compared the 99 validated genes from our second cohort in TNBC samples (16) versus non-TNBC samples (48) and discovered that 28 of these genes are specific to TNBC. In the TCGA cohort we compared the 95 validated genes to the expression of 313 non-TNBC samples, which identified 14 TNBC specific genes. There are 4 TNBC specific genes that are common in both cohorts; these are ANKRD30A, ANP32E, DSC2 and IL6ST.